RECEIVABLES	9 Months Ended
Sep. 30, 2017
Receivables [Abstract]
RECEIVABLES	RECEIVABLES Accounts Receivables Accounts receivable, net of reserves for prompt pay discounts and doubtful accounts, was $14.5 million and $18.5 million at September 30, 2017 and December 31, 2016, respectively. The total reserves for both periods were immaterial. Notes Receivables The notes receivable arose from the Company's sale of a Pediatric Priority Review Voucher in July 2015 to Sanofi for $245.0 million. $150.0 million was received upon closing, and $47.5 million was due on each of the first and second anniversaries of the closing. In accordance with GAAP, the Company recorded the future short term and long term notes receivable at their present value of $46.2 million and $44.9 million, respectively, at the date of the sale using a discount rate of 2.8%. The accretion on the notes receivable totaled $0.6 million for the nine months ended September 30, 2017, and is recorded in interest expense, net, in the Consolidated Statements of Operations and Comprehensive Loss. The first anniversary payment was received on July 2, 2016. The second anniversary payment was received on June 30, 2017. The note receivable balances as of September 30, 2017 and December 31, 2016 were zero and $46.8 million, respectively.

RECEIVABLES

Accounts Receivables

Accounts receivable, net of reserves for prompt pay discounts and doubtful accounts, was $14.5 million and $18.5 million at September 30, 2017 and December 31, 2016, respectively. The total reserves for both periods were immaterial.

Notes Receivables

The notes receivable arose from the Company's sale of a Pediatric Priority Review Voucher in July 2015 to Sanofi for $245.0 million. $150.0 million was received upon closing, and $47.5 million was due on each of the first and second anniversaries of the closing. In accordance with GAAP, the Company recorded the future short term and long term notes receivable at their present value of $46.2 million and $44.9 million, respectively, at the date of the sale using a discount rate of 2.8%. The accretion on the notes receivable totaled $0.6 million for the nine months ended September 30, 2017, and is recorded in interest expense, net, in the Consolidated Statements of Operations and Comprehensive Loss.

The first anniversary payment was received on July 2, 2016. The second anniversary payment was received on June 30, 2017. The note receivable balances as of September 30, 2017 and December 31, 2016 were zero and $46.8 million, respectively.